GlobeNewswire

Oasmia publishes its annual report and adjusts accounts due to write-downs - auditors do not recommend former board to be granted discharge from liability

Share

Oasmia Pharmaceutical AB's annual report for the fiscal year 2018/2019 is now available on the company's website www.oasmia.com. Compared to the year-end report, which was published on June 28, the financial statements for the fiscal year have been adjusted as a result of non-cash flow write-downs of SEK 30.9 million. The result for the year and equity are therefore negatively affected by the same amount. The company's auditors also recommend that members of the former board not to be discharged from liability.

The write-downs mainly relate to balanced development costs of SEK 25.0 million in the project KB9520, which was acquired from Karo Bio in 2016. In addition, write-downs refer to inventories of SEK 5.5 million and other items of SEK 0.4 million.

Oasmia's auditors PwC do not recommend that the members of the former Board of Directors, Julian Aleksov, Lars Bergkvist, Bo Cederstrand, Alexander Kotsinas and Per Langö, to be granted discharge from liability. PWC however recommends that former CEO Mikael Asp is to be granted discharge from liability, as well as the members of the current Board of Directors Jörgen Olsson, Gunilla Öhman, Sven Rohmann and Peter Zonabend.

This information is inside information that Oasmia Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and information that Oasmia Pharmaceutical AB (publ) is obliged to make public pursuant to the Securities Market Act. The information was submitted for publication, through the agency of the contact person set out above, at 15.00 CET on September 5, 2019.

For more information:
Investor Relations Oasmia
E-mail: IR@oasmia.com

About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures, markets and sells new generations of drugs in the field of human and veterinary oncology. The company’s product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company’s product development is based on its proprietary in-house research and company patents. Oasmia is listed on Frankfurt Stock Exchange (OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).

Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Aino Health AB (publ): KALLELSE TILL EXTRA BOLAGSSTÄMMA I AINO HEALTH AB (PUBL)9.8.2020 19:15:00 CESTPressemelding

Aktieägarna i Aino Health (publ), org.nr 559063-5073 (”Bolaget”) kallas härmed till extra bolagsstämma onsdagen den 9 september 2020 i Stockholm. Med anledning av Coronapandemin (Covid-19) kommer den extra bolagsstämman att genomföras endast genom poströstning. Detta betyder att aktieägarna i Bolaget inte har rätt att närvara vid stämman, varken personligen eller genom ombud. Istället har aktieägarna rätt att utöva sin rösträtt per post genom att rösta i förväg enligt instruktionerna i denna kallelse. Rätt att delta vid stämman På grund av Coronapandemin och för att säkerställa aktieägares, anställdas och andra intressenters hälsa och säkerhet har styrelsen för Bolaget beslutat att aktieägarna inte ska ha rätt att närvara vid stämman, varken personligen eller genom ombud, och att den som inte är aktieägare inte ska ha rätt att närvara i enlighet med 20–26 §§ i lagen (2020:198) om tillfälliga undantag för att underlätta genomförandet av bolags- och föreningsstämmor. Aktieägarna har istä

Aino Health AB (publ): Aino Health decides on a fully secured rights issue of shares of approximately SEK 15.9 million9.8.2020 19:05:00 CESTPress release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SWITZERLAND, SINGAPORE, SOUTH AFRICA, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, BE SUBJECT TO LEGAL RESTRICTIONS OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES. The Board of Directors of Aino Health AB (publ) (“Aino Health” or the “Company”) has, subject to approval at the Extraordinary General Meeting on 9 September 2020, decided to carry out a rights issue of a maximum of 10,623,319 shares (the “Rights issue”). The subscription price per share is SEK 1.50, whereby Aino Health upon full subscription in the Rights issue receives approximately SEK 15.9 million before issue costs. For every (1) existing share on the record date on 16 September 2020, two (2) subscription rights are received and three (3) subscription rights entitle the holder to subscribe for one (1)

Aino Health AB (publ): Aino Health beslutar om en fullt säkerställd företrädesemission av aktier om cirka 15,9 MSEK9.8.2020 19:05:00 CESTPressemelding

EJ FÖR OFFENTLIGGÖRANDE, PUBLICERING ELLER DISTRIBUTION, DIREKT ELLER INDIREKT, INOM ELLER TILL USA, AUSTRALIEN, KANADA, NYA ZEELAND, HONGKONG, JAPAN, SCHWEIZ, SINGAPORE, SYDAFRIKA, ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDET, PUBLICERINGEN ELLER DISTRIBUTIONEN AV DETTA PRESSMEDDELANDE SKULLE VARA OLAGLIG, VARA FÖREMÅL FÖR LEGALA RESTRIKTIONER ELLER SKULLE KRÄVA REGISTRERING ELLER ANDRA ÅTGÄRDER. Styrelsen för Aino Health AB (publ) (”Aino Health” eller ”Bolaget”) har, förutsatt godkännande på extra bolagsstämman den 9 september 2020, beslutat att genomföra en företrädesemission av högst 10 623 319 aktier (”Företrädesemissionen”). Teckningskursen per aktie är 1,50 SEK, varigenom Aino Health vid full teckning i Företrädesemissionen erhåller cirka 15,9 MSEK före emissionskostnader. För varje (1) befintlig aktie på avstämningsdagen den 16 september 2020 erhålls två (2) teckningsrätter och tre (3) teckningsrätter berättigar till teckning av en (1) ny aktie. Teckningsperioden löpe

CONDITIONS FOR RIKSBANK BID PROCEDURE KOMMUNINVEST BONDS7.8.2020 16:20:00 CESTPress release

Sveriges Riksbank Bid procedure details Kommuninvest Bonds, 2020-08-11 Maturity dateLoanISIN codeCouponVolume, SEK million2021-09-152109 SE00069950641.00 %500+/- 2502023-02-222302 SE00096629430.75 %500+/- 2502024-10-022410 SE00104692051.00 % 500+/- 250 2026-02-042602 SE00137454520.75 % 500+/- 250 Maximum volume 2 BLN in total Settlement date 2020-08-13 Bids have to be entered by 11.00 on AUG 11, 2020 Highest permitted bid volume: 500 SEK million in issue 2109, 2302, 2410, and 2602. Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 11.15 (CEST) ON AUG 11, 2020 For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se

CONDITIONS FOR RIKSBANK BID PROCEDURES SEK GOVERNMENT BONDS7.8.2020 16:20:00 CESTPress release

Sveriges Riksbank Bid procedure details Government Bonds, 2020-08-14 Maturity dateLoanISIN codeCouponVolume, SEK million2029-11-12 1061SE00112819220.75 %500 +/- 2502032-06-01 1056SE00045172902.25 %500 +/- 250 Settlement date 2020-08-18 Bids have to be entered by 10.00 on AUG 14, 2020 Highest permitted bid volume: 500 SEK million in issue SGB 1061 and 500 SEK million in issue SGB 1056 Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.10 (CEST)ON AUG 14, 2020. For more information, please contact: Trading desk at the Riksbank + 46 8 696 6970 General and special terms and conditions can be retrieved at http://www.riksbank.se

CONDITIONS FOR RIKSBANK BID PROCEDURES SEK COVERED BONDS7.8.2020 16:20:00 CESTPress release

Sveriges Riksbank Bid procedure details Covered Bonds, 2020-08-13 Maturity dateLoanISIN codeCouponVolume, SEK million2023-09-20 5533 SE00104427311.25 %1,000 +/- 5002022-12-21 575 SE00105465721.50 %1,000 +/- 500 2023-06-011587SE00104413031.50 %1,000 +/- 5002023-03-15192SE00101332071.00 %1,000 +/- 5002022-12-212212SE00102970851.00 %400 +/- 2502023-09-20516SE00091903901.25 %400 +/- 2502023-06-21144SE00111674281.00 %400 +/- 250 Settlement date 2020-08-17 Bids have to be entered by 10.00 on AUG 13 2020 Highest permitted bid volume: 1,000 SEK million in issue 5533 1,000 SEK million in issue 575 1,000 SEK million in issue 1587 1,000 SEK million in issue 192 400 SEK million in issue 2212 400 SEK million in issue 516 400 SEK million in issue 144 Maximum volume 5 billion SEK in total Lowest permitted bid volume: 50 SEK million Bids only through counterparties approved by the Riksbank RESULT OF AUCTION WILL BE PUBLISHED NO LATER THAN 10.15 (CEST) ON AUG 13, 2020. For more information, please cont